FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310945370> ?p ?o ?g. }

• W4310945370 endingPage "7326" @default.
• W4310945370 startingPage "7309" @default.
• W4310945370 abstract "SPRY4-IT1 (SPRY4 intronic transcript 1) is a long non-coding RNA (lncRNA) that has been identified as a novel oncogene in various cancers, including glioma. However, its function and underlying mechanism in glioma remain largely unclear. Here, we investigated the role of SPRY4-IT1 in the development of glioma and its underlying mechanism.Bioinformatics analysis and RT-qPCR assay were used to examine the expression of SPRY4-IT1 in glioma tissues. The CCK-8, EdU, and Xenograft tumor assays wereperformed to assess the proliferation effect of glioma cells. The tube forming assay and Chick Embryo Chorioallantoic Membrane (CAM) assay were conducted to detect the angiogenesis effect of HUVECs. RNA-sequencing, western blotting, RT-qPCR, ELISA, and IHC assays were employed to verify the regulatory mechanism of the SPRY4-IT1/ miR-101-3p/EZH2/VEGFA axis.Analysis of the TCGA dataset and data from our own cohort demonstrated that SPRY4-IT1 was overexpressed in patients with glioma, and high SPRY4-IT1 expression correlated with poor prognosis. In vitro and in vivo experiments showed that SPRY4-IT1 promoted the proliferation of glioma cells. RNA sequencing and Gene Ontology (GO) enrichment analysis indicated significant enrichment of angiogenesis. HUVEC tube forming assay and CAM assay confirmed that SPRY4-IT1 could induce angiogenesis of glioma cells in vitro and in vivo. Mechanistically, SPRY4-IT1 upregulated EZH2 expression by sponging miR-101-3p to induce VEGFA expression in glioma cells. Moreover, SPRY4-IT1 activated the VEGFR2/AKT/ERK1/2 pathway in HUVECs mediated by glioma cells. Rescue experiments further confirmed that SPRY4-IT1 promoted glioma cell proliferation and angiogenesis via the miR-101-3p/EZH2/VEGFA signaling axis.Our findings provide compelling evidence showing that SPRY4-IT1 upregulated EZH2 to induce VEGFA by sponging miR-101-3p, thereby achieving cell proliferation and angiogenesis in glioma. Therefore, targeting SPRY4-IT1/miR-101-3p/EZH2/VEGFA axis may improve the outcomes of patients with glioma." @default.
• W4310945370 created "2022-12-21" @default.
• W4310945370 creator A5000015876 @default.
• W4310945370 creator A5017804963 @default.
• W4310945370 creator A5021405510 @default.
• W4310945370 creator A5025908815 @default.
• W4310945370 creator A5040558103 @default.
• W4310945370 creator A5041685367 @default.
• W4310945370 creator A5042040601 @default.
• W4310945370 creator A5050661386 @default.
• W4310945370 creator A5065388588 @default.
• W4310945370 creator A5065918472 @default.
• W4310945370 creator A5071728973 @default.
• W4310945370 creator A5072315367 @default.
• W4310945370 creator A5083289271 @default.
• W4310945370 date "2022-12-07" @default.
• W4310945370 modified "2023-10-12" @default.
• W4310945370 title "LncRNA SPRY4‐IT1 facilitates cell proliferation and angiogenesis of glioma via the miR‐101‐3p/EZH2/VEGFA signaling axis" @default.
• W4310945370 cites W1917706778 @default.
• W4310945370 cites W1976149758 @default.
• W4310945370 cites W1989904037 @default.
• W4310945370 cites W2033776879 @default.
• W4310945370 cites W2070412580 @default.
• W4310945370 cites W2083898865 @default.
• W4310945370 cites W2108301702 @default.
• W4310945370 cites W2117692326 @default.
• W4310945370 cites W2133180880 @default.
• W4310945370 cites W2164346983 @default.
• W4310945370 cites W2293809486 @default.
• W4310945370 cites W2305883580 @default.
• W4310945370 cites W2335029242 @default.
• W4310945370 cites W2511206720 @default.
• W4310945370 cites W2559569254 @default.
• W4310945370 cites W2566052798 @default.
• W4310945370 cites W2595756570 @default.
• W4310945370 cites W2784570320 @default.
• W4310945370 cites W2788281894 @default.
• W4310945370 cites W2791638837 @default.
• W4310945370 cites W2797630761 @default.
• W4310945370 cites W2886993778 @default.
• W4310945370 cites W2890167767 @default.
• W4310945370 cites W2894860758 @default.
• W4310945370 cites W2898597108 @default.
• W4310945370 cites W2914809873 @default.
• W4310945370 cites W2945223560 @default.
• W4310945370 cites W2955814629 @default.
• W4310945370 cites W2957523941 @default.
• W4310945370 cites W2996284151 @default.
• W4310945370 cites W3006197480 @default.
• W4310945370 cites W3031224726 @default.
• W4310945370 cites W3033498185 @default.
• W4310945370 cites W3083237971 @default.
• W4310945370 cites W3160204978 @default.
• W4310945370 cites W3169559382 @default.
• W4310945370 cites W3204396365 @default.
• W4310945370 cites W4206712529 @default.
• W4310945370 cites W4211220688 @default.
• W4310945370 doi "https://doi.org/10.1002/cam4.5517" @default.
• W4310945370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36479622" @default.
• W4310945370 hasPublicationYear "2022" @default.
• W4310945370 type Work @default.
• W4310945370 citedByCount "1" @default.
• W4310945370 countsByYear W43109453702023 @default.
• W4310945370 crossrefType "journal-article" @default.
• W4310945370 hasAuthorship W4310945370A5000015876 @default.
• W4310945370 hasAuthorship W4310945370A5017804963 @default.
• W4310945370 hasAuthorship W4310945370A5021405510 @default.
• W4310945370 hasAuthorship W4310945370A5025908815 @default.
• W4310945370 hasAuthorship W4310945370A5040558103 @default.
• W4310945370 hasAuthorship W4310945370A5041685367 @default.
• W4310945370 hasAuthorship W4310945370A5042040601 @default.
• W4310945370 hasAuthorship W4310945370A5050661386 @default.
• W4310945370 hasAuthorship W4310945370A5065388588 @default.
• W4310945370 hasAuthorship W4310945370A5065918472 @default.
• W4310945370 hasAuthorship W4310945370A5071728973 @default.
• W4310945370 hasAuthorship W4310945370A5072315367 @default.
• W4310945370 hasAuthorship W4310945370A5083289271 @default.
• W4310945370 hasBestOaLocation W43109453701 @default.
• W4310945370 hasConcept C104317684 @default.
• W4310945370 hasConcept C127561419 @default.
• W4310945370 hasConcept C153911025 @default.
• W4310945370 hasConcept C2778227246 @default.
• W4310945370 hasConcept C2780394083 @default.
• W4310945370 hasConcept C502942594 @default.
• W4310945370 hasConcept C54355233 @default.
• W4310945370 hasConcept C62203573 @default.
• W4310945370 hasConcept C86803240 @default.
• W4310945370 hasConceptScore W4310945370C104317684 @default.
• W4310945370 hasConceptScore W4310945370C127561419 @default.
• W4310945370 hasConceptScore W4310945370C153911025 @default.
• W4310945370 hasConceptScore W4310945370C2778227246 @default.
• W4310945370 hasConceptScore W4310945370C2780394083 @default.
• W4310945370 hasConceptScore W4310945370C502942594 @default.
• W4310945370 hasConceptScore W4310945370C54355233 @default.
• W4310945370 hasConceptScore W4310945370C62203573 @default.
• W4310945370 hasConceptScore W4310945370C86803240 @default.
• W4310945370 hasFunder F4320321001 @default.
• W4310945370 hasIssue "6" @default.

• next